Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| G1 Therapeutics Inc | GTHX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 4.17 | 04:03:28 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.17 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.08 - 5.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 4.17 | USD |
G1 Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 217.67M | 52.20M | - | 82.51M | -47.97M | -0.92 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
G1 Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GTHX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.65 | 4.695 | 3.99 | 4.28 | 629,026 | -0.48 | -10.32% |
| 1 Month | 3.72 | 4.895 | 3.69 | 4.46 | 874,283 | 0.45 | 12.10% |
| 3 Months | 3.83 | 5.00 | 2.01 | 3.53 | 1,347,864 | 0.34 | 8.88% |
| 6 Months | 1.29 | 5.00 | 1.2666 | 3.12 | 1,349,813 | 2.88 | 223.26% |
| 1 Year | 2.78 | 5.00 | 1.08 | 2.82 | 1,078,534 | 1.39 | 50.00% |
| 3 Years | 23.44 | 24.12 | 1.08 | 7.92 | 1,051,331 | -19.27 | -82.21% |
| 5 Years | 18.45 | 41.80 | 1.08 | 11.87 | 908,021 | -14.28 | -77.40% |
G1 Therapeutics Description
| G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat most types of cancer, such as cell lung cancer and breast cancer, and designs them to combine - and enhance - the anti-tumor activity of current therapies. |
